GeNeuro has this week reported positive results from the ANGEL-MS study of its lead product, temelimab in multiple sclerosis (MS).
Temelimab is a humanised, monoclonal antibody designed to neutralise pHERV-W, a pathogenic protein thought to be a causal factor in the development of MS.
The data confirmed that treatment with temelimab for 2 years had a continued, positive impact on key MRI measures of disease progression in multiple sclerosis patients, confirming and extending the data reported at Week 48 in the CHANGE-MS Phase 2b study.
This includes reductions in brain atrophy – particularly in the cortex and thalamus – and maintenance in myelin integrity, as measured by magnetisation transfer ratio (MTR) imaging.
For the first time, encouraging dose-dependent effects were seen on clinical measures of disease progression. This has been evidenced by a lower proportion of patients with 12-week confirmed EDSS progression, or with 20% worsening in 25-foot timed walk.
Jesús Martin-Garcia, CEO of GeNeuro, said: “The results of ANGEL-MS confirm the potential of temelimab to act against disease progression, the largest unmet medical need in this indication. It further reinforces our determination to continue the development of temelimab in MS.”
Prof Hans-Peter Hartung, Chairman of the Department of Neurology of the University Hospital Düsseldorf and Lead Investigator of the study, added: “These results are remarkable, and they are coherent with temelimab’s novel mode of action seeking to stop the activation of the brain’s innate immunity and restoring the myelin repair system.
“It offers promise to treat progressive patients with low inflammatory activity, and could have potential synergies with existing anti-inflammatory drugs in relapsing MS patients.”